SCHEMBL1607758

SCHEMBL1607758

COc1ccc(-c2noc(-c3ccc4cc[nH]c4c3)n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.62
RAB9A P51151 11/20 0.60
NPC1 O15118 10/20 0.60
MAPT P10636 9/20 0.60
SMN1; SMN2 Q16637 7/20 0.60
HPGD P15428 3/20 0.60
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 2/20 0.60
NPSR1 Q6W5P4 2/20 0.58
NR1H4 Q96RI1 1/20 0.58
LMNA P02545 2/20 0.55
HSD17B10 Q99714 1/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
POLB P06746 2/20 0.55
MAPK1 P28482 1/20 0.55
NFKB1 P19838 3/20 0.52
NFKB2 Q00653 3/20 0.52
RELA Q04206 3/20 0.52
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250936 0.90 S1PR1 (0.62) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL30620465 0.80 MEN1 (0.73) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL1224829 0.80 MEN1 (0.73) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL12895918 0.80 RAB9A (0.76) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL18284221 0.77 BRD4 (0.58) S1PR1MAPTLMNAMEN1KMT2A
SCHEMBL1608484 0.77 MAPT (0.56) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL13416929 0.77 S1PR1 (1.00) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12692350 0.76 NPC1 (0.86) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL21153250 0.76 S1PR1 (0.58) S1PR1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1423263 0.75 NPC1 (0.66) S1PR1RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 S1PR1 917/4885RAB9A 4026/4885NPC1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.